Fate Therapeutics (NASDAQ: FATE) granted inducement awards on February 1, 2026 to a newly-hired non-executive employee under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The package includes 120,000 non-qualified stock options at an exercise price of $1.19 per share and 90,000 restricted stock units (RSUs). Options vest over four years (25% at one year, remainder monthly over 36 months); RSUs vest 25% each anniversary over four years, subject to continued employment.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – FATE
-0.86%
6 alerts
-0.86%News Effect
-2.2%Trough in 26 hr 50 min
-$1MValuation Impact
$133MMarket Cap
0.8xRel. Volume
On the day this news was published, FATE declined 0.86%, reflecting a mild negative market reaction.
Argus tracked a trough of -2.2% from its starting point during tracking.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
This price movement removed approximately $1M from the company's valuation, bringing the market cap to $133M at that time.
Current price:$1.23Daily change:3.36%Stock options granted:120,000 shares+5 more
8 metrics
Current price$1.23Price before publication of inducement award news
Daily change3.36%Price change over prior 24 hours
Stock options granted120,000 sharesNon-qualified stock options to one newly hired non-executive employee
Option exercise price$1.19 per shareExercise price equal to NASDAQ close on January 30, 2026
RSUs granted90,000 sharesRestricted stock units to the same new employee
Option vesting schedule4 years25% after 1 year, then monthly over 36 months
RSU vesting schedule4 years25% on each anniversary of the grant date
52-week range vs high-36.59%Current price vs 52-week high of $1.9399
Market Reality Check
Price:$1.10Vol:Volume 1,664,274 shares i...
normal vol
$1.10Last Close
VolumeVolume 1,664,274 shares is slightly below the 20-day average of 1,839,284 shares.normal
TechnicalTrading modestly above the 200-day MA, with price at $1.23 vs 200-day MA of $1.16.
Peers on Argus
FATE was up 3.36% while peers were mixed: CRBP +0.73%, EQ +7.86%, FBRX +18.81%, ...
FATE was up 3.36% while peers were mixed: CRBP +0.73%, EQ +7.86%, FBRX +18.81%, KALA +4.52%, and TARA -0.28%, suggesting company-specific trading rather than a uniform sector move.
RSU inducement grants to three new non-executive employees under Nasdaq Rule 5635(c)(4).
Pattern Detected
Positive clinical and earnings updates have previously seen mixed-to-negative next-day moves, while routine inducement award announcements have produced small, mixed price reactions.
Recent Company History
Recent news for FATE includes multiple inducement equity awards under Nasdaq Rule 5635(c)(4) on Nov 1, 2025 and Jan 1, 2026, both tied to non-executive hires. The stock also responded to an earnings update on Nov 13, 2025 that detailed cash of $225.7M and reduced operating expenses, as well as positive clinical trial updates for FT819. Against this backdrop, today’s single-employee inducement grant continues a pattern of routine equity-based compensation disclosures.
Market Pulse Summary
This announcement details a routine inducement grant of 120,000 stock options at $1.19 and 90,000 RS...
Analysis
This announcement details a routine inducement grant of 120,000 stock options at $1.19 and 90,000 RSUs to a new employee under Nasdaq Listing Rule 5635(c)(4), with four-year vesting. It continues FATE’s pattern of equity-based compensation alongside prior insider grants reported in recent Form 4 filings. With shares at $1.23, above the $1.16 200-day MA but 36.59% below the 52-week high, this news does not alter the company’s fundamental outlook on its own.
Key Terms
induced pluripotent stem cell (ipsc), cellular immunotherapies, non-qualified stock options, restricted stock units (rsus), +2 more
6 terms
induced pluripotent stem cell (ipsc)medical
"a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular"
Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, able to develop into many different cell types. Think of them as retrained workers who can be reassigned to multiple jobs; for investors they matter because iPSCs enable development of new therapies, personalized drug testing, and scaled cell products, which can drive long-term value but also face lengthy development timelines and regulatory scrutiny.
cellular immunotherapiesmedical
"iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune"
Cellular immunotherapies are medical treatments that use living immune cells, taken from a patient or donor and then trained, modified, or expanded in a lab so they better recognize and attack disease, such as cancer or infection. For investors, these therapies matter because they can offer dramatic, durable patient responses and premium pricing but also carry high development, manufacturing and regulatory risks—think of them as highly trained sniffer dogs that can be powerful but expensive and complex to deploy.
non-qualified stock optionsfinancial
"the Company granted to one newly-hired non-executive employee (i) non-qualified stock options"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock units (rsus)financial
"and (ii) restricted stock units (RSUs) representing 90,000 shares of its common stock."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
nasdaq listing rule 5635(c)(4)regulatory
"with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"stock at an exercise price per share of $1.19, which was the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. Not financial advice.
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) non-qualified stock options to purchase a total of 120,000 shares of the Company’s common stock at an exercise price per share of $1.19, which was the closing price per share of the Company’s common stock as reported by NASDAQ on January 30, 2026, and (ii) restricted stock units (RSUs) representing 90,000 shares of its common stock. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Ryan Douglas Fate Therapeutics, Inc. IR@fatetherapeutics.com
FAQ
What inducement awards did Fate Therapeutics (FATE) grant on February 1, 2026?
Fate granted 120,000 stock options and 90,000 RSUs to a newly-hired non-executive employee. According to the company, the options have a $1.19 exercise price and both awards vest over four years subject to continued employment.
What is the exercise price and reference date for the FATE option grant?
The exercise price is $1.19 per share, based on the closing NASDAQ price on January 30, 2026. According to the company, that closing price served as the option strike for the inducement award.
How do the FATE option vesting terms work for the 120,000-share grant?
Options vest over four years with 25% at the one-year anniversary and the remainder vesting monthly over 36 months. According to the company, vesting is conditioned on the employee's continuous employment through each vesting date.
What are the vesting terms for the 90,000 RSUs granted by Fate (FATE)?
The 90,000 RSUs vest over four years with 25% vesting on each anniversary of the grant date. According to the company, RSU vesting requires the employee to remain continuously employed through each anniversary.
Under what plan and listing rule were the FATE inducement awards granted?
The awards were granted under the company's Amended and Restated Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4). According to the company, the Compensation Committee approved the awards as an inducement material to hiring.
